First COPD Patient Enrolled in Phase 4 Study of Yupelri vs. Spiriva

First COPD Patient Enrolled in Phase 4 Study of Yupelri vs. Spiriva

316215

First COPD Patient Enrolled in Phase 4 Study of Yupelri vs. Spiriva

A first patient has been enrolled in a Phase 4 study of the effectiveness of Yupelri (revefenacin) against Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD). The respective safety of these two approved, once-daily COPD maintenance treatments will also be evaluated. Yupelri, developed by Theravance Biopharma and Mylan (now part of Viatris), is a bronchodilator, a type of medication that relaxes and widens the lung airways, making breathing easier. It is available as…

You must be logged in to read/download the full post.